Leprosy is a complex chronic, infectious dermato-neurological disease that affects the skin and peripheral nerves especially during immuno-inflammatory episodes known as type 1/T1R and type 2/T2R reactions. This study investigated the in situ expression of CD25+Foxp3+ Treg cells and TGF-β1, IFN-γ, IL-17 in leprosy T1R and T2R. Tregs were evaluated in 114 skin biopsies from 74 leprosy patients: 56 T1R (28-paired reaction-free/reactional biopsies, 28 unpaired T1R), 18 T2R (12 paired reaction-free/reactional biopsies, 6 unpaired T2R). Double CD25+Foxp3+immunostained Treg cells obtained by automated platform (Ventana BenchMark XT, Roche, Mannheim, Germany) were counted (Nikon Eclipse E400 2mm2). Cytokine expression was evaluated by immunostaining in 96 biopsies (48 paired reaction-free/reactional lesions, 24 T1R, 24 T2R) using rabbit polyclonal anti human TGF-β1, IFN-γ, IL-17 antibodies (Santa Cruz Biotechnology CA, USA). Treg cell counts in leprosy reactional lesions were higher compared to reaction-free (p = 0.002). Treg numbers were higher in T1R compared to paired unreactional T1R lesions (p = 0.001). Similar frequency of Treg was seen in paired reactional versus unreactional T2R lesions. Higher expression of TGF-β, IFN-γ and IL-17 was seen in T2R lesions compared to T1R and reaction-free lesions. The increase in Treg cells during T1R suggests a suppressive role to control the exacerbated cellular immune response during T1R that can cause tissue and nerve damage. Evidences of upregulated Treg cells in TR1, which usually occurs in patients with Th1-Th17 immunity and the indications of the expression of Th17/IL-17 in T2R, which develops in patients with Th2-Treg profile, suggest plasticity of Treg-Th17 cells populations and a potential role for these cell populations in the immunopathogenesis of leprosy reactions.
Citation: Costa MB, Hungria EM, Freitas AA, Sousa ALOM, Jampietro J, Soares FA, et al. (2018) In situ T regulatory cells and Th17 cytokines in paired samples of leprosy type 1 and type 2 reactions. PLoS ONE 13(6): e0196853. https://doi.org/10.1371/journal.pone.0196853
Editor: Lucienne Chatenoud, Université Paris Descartes, FRANCE
Received: December 27, 2017; Accepted: April 20, 2018; Published: June 8, 2018
Copyright: © 2018 Costa et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by the Programa de Apoio a Núcleos de Excelência (PRONEX), Fundação de Amparo à Pesquisa do Estado de Goiás (FAPEG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ) (PRONEX/FAPEG/CNPQ Grant number 007/2009) (MMAS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Leprosy is a complex chronic, infectious dermato-neurological disease that affects the skin and peripheral nerves. Leprosy can lead to significant impairment of nerve function and permanent deformities, which are the hallmark of the disease . Multidrug therapy (MDT), available since the 80’s has reduced prevalence; however, incidence remains stable indicating active transmission chains of its etiologic agent, Mycobacterium leprae . Leprosy still represents an important public health problem in many endemic countries as India and Brazil . The disease is characterized by a wide spectrum of clinical, immunologic, microbiologic and histopathologic manifestations which can be classified as tuberculoid (TT), borderline tuberculoid (BT), borderline-borderline (BB), borderline lepromatous (BL) and lepromatous leprosy .
For decades the Th1-Th2 paradigm was associated with leprosy manifestations but more recently other CD4+ T cell populations as Th17 and T regulatory cells (Treg) have been implicated in the immunopathology of leprosy . According to these, paucibacillary patients (PB) that comprise TT and BT forms, present low bacillary load, few localized lesions and develop inflammatory Th1 type and Th17 cell-mediated immunity (CMI) to M. leprae with low antibody production [6–8]. On the other end of the spectrum, multibacillary patients (MB), which include BB, BL and LL forms, show multiple skin lesions, high bacillary load, Th2 type immunity with vigorous antibody production and higher expression of Treg cells [9–12].
One of the major complications in the clinical management of leprosy patients is the development of acute immune inflammatory episodes, known as leprosy reactions, during the chronic course of the disease either before, during or after the specific treatment. Type 1 and type 2 reactions (T1R and T2R) are the main manifestations of leprosy reactions. These episodes are responsible for irreversible nerve damage representing the major cause of permanent physical disabilities and deformities . Contradictory results and interpretations have been reported about the role of Treg cells in the immunopathogenesis of leprosy reactions [14–20]. Several relevant methodological differences and more importantly, the use of different compositions of comparative control groups limit comparisons among these studies. Intra-individual comparisons in paired samples, collected in the course of a reactional episode and when the patient is reaction free, provide the best comparative control possible. In this context, the current study describes in situ expression of Treg cells and cytokines with emphasis in paired skin biopsies of T1R and T2R leprosy patients.
Materials and methods
Our study group comprised 74 leprosy patients that developed leprosy reaction including 56 cases of T1R and 18 cases of T2R. Leprosy patients were recruited at a public health reference center (Centro de Referência em Diagnóstico e Terapêutica, CRDT, Goiânia, Goiás State, central West Brazil). All patients were submitted to a complete dermato-neurologic examination by one dermatologist with vast expertise in leprosy diagnosis (ALOMS) and skin biopsies were taken from typical and active leprosy skin lesions. Leprosy patients were classified according to a modified Ridley & Jopling criteria taking into account histopathology, bacilloscopy in the lesion and clinical data.
Case definition for T1R was acute inflammation of pre-existing cutaneous lesions with or without the appearance of new lesions. T1R patients were diagnosed based on clinical signs and symptoms which were not always associated with a specific histopathological finding, so that often the histopathology of T1R lesion was similar to the histopathology of a skin lesion taken from a reaction-free patient of a similar Ridley Jopling category. When histopathological modifications were seen in T1R, these included edema, looser granulomas and sometimes necrosis foci occasionally with bacilli. Case definition for T2R was based on the acute appearance of erythematous nodular skin lesions, tender to touch or painful, in the absence of external stimuli, accompanied by fever with or without peripheral nerve pain and dysfunction. In T2R, the prevailing histopathological findings were the ones characteristic of erythema nodosum leprosum/ENL, such as panniculitis with leukocytoclastic vasculitis in small vessels and neutrophilic infiltrates occasionally with fragmented bacilli, in smaller numbers than found in reaction-free patients.
Based on dermato-neurologic examination, reaction-free patients were defined as the ones who did not have at the moment of examination any sign or symptom of type 1 nor type 2 reactional episodes.
Leprosy patients received standard treatment according to the WHO recommended regimen: 6 doses MDT (rifampicin, dapsone) for paucibacillary patients (< = five skin lesions) to be taken up to 9 months and for multibacillary patients (> = 6 skin lesions) 12 doses MDT (rifampicin, dapsone, clofazimine) during up to 18 months. For type 1 reaction the anti- reaction treatment consisted of standard- 12 weeks course of oral prednisolone (up to 1mg/kg/day). After this period, the dose was gradually reduced, decreasing 10mg each 15 days, up to 5mg/kg which was maintained for 12 weeks. To treat T2R, if not contraindicated (4 women of childbearing age), thalidomide (100-400mg/day) was used at night. Another alternative was the same oral prednisolone treatment used to treat T1R. If T2R occurred with neuritis, thalidomide and prednisolone were used concomitantly.
In our study among 28 T1R patients with paired samples, 20 were diagnosed during the reactional episode when the first skin biopsies were taken. For these patients, the second skin biopsy was taken after a median time of 12 months. The remaining 8 patients that were reaction-free at diagnosis had their first skin biopsy collected at diagnosis and they developed T1R around 9 months after the diagnosis (6–14 months range), when the second skin biopsy was taken. Among the 12 patients that developed T2R, 7 were diagnosed during the reactional episode when the first biopsy was collected and the second biopsy was taken at a mean time of 12 months after the diagnosis/reaction. The remaining 5 patients were reaction free at diagnosis when the first skin biopsy was taken; their T2R occurred at a mean time of 12 months after the diagnosis, when the second biopsy was collected. Leprosy patients were monitored for 18 months after diagnosis and our study did not include extended follow-up. Therefore, during the study period, all patients presented only a single reactional episode and the investigation of possible occurrence of multiple reactional episodes overtime was not part of the study.
The main demographic and clinical features of our study population is depicted in Table 1. Most leprosy patients was male (66.2%, 49 out of 74) and the median age was 48 years (20–75 years range). Patients that developed T1R (n = 56) presented a wide range of clinical manifestations at diagnosis (3 TT, 28 BT, 02 BB, 22 BL and 01 LL) with either negative or low bacillary counts in the lesions. T2R group (n = 18) included 09 BL and 09 LL patients all of them with detectable bacilli in the lesion (median = 3.5, range 1–6).
Skin biopsies, histopathology
Biopsies were taken from the edges of well-characterized and infiltrated skin lesions using standard dermatologic biopsy punches (4mm). Fixation was performed with 10% neutral buffered formalin in 4% formaldehyde for 24 hours. Skin biopsy lesions (3–4 μm sections) were stained by hematoxylin-eosin (HE) and by Fite-Faraco for histopathology examination and bacilli detection/counts. The whole inflammatory infiltrate was analyzed and after this, 8 fields of 400X were selected to perform cell/cytokine countings and these 8 fields correspond to 2 mm2. In this study, the emphasis of infiltrates of T1R versus T2R was given on Tregs and the selected cytokines.
Double immunohistochemical detection of CD25+Foxp3+Treg cells
For the immunohistochemical study, skin biopsies were deparaffinized (EZPrep, Roche), treated with Cell Conditioner (Roche) and submitted to heat induced antigen retrieval. Double immunostaining reaction to detect CD25/Foxp3 coexpression was performed using an automated platform (Ventana BenchMark XT, Roche, Mannheim, Germany). The ultra-View Universal DAB detection kit (Roche, Germany) was used for CD25 staining with primary antibody–horseradish peroxidase/HRP labeled complex (anti-human monoclonal antibody, clone 4C9, Ventana, Roche, Tucson, AZ, USA) resulting in a brown/black target signal. Foxp3 staining employed anti-Foxp3+ antibodies (mice anti-human monoclonal antibodies, clone 236A/E7, Abcam, Cambridge, UK) and the ultra-View Universal Alkaline Phosphatase Red Detection Kit (Roche, Manhein, Germany). The primary antibody–alkaline phosphatase labeled complex was visualized using Fast Red/Naphthol resulting in a bright red target signal. Slides were washed and Hematoxylin II (Roche, Mannheim, Germany) was added, incubated, washed and the Bluing Reagent (Roche, Mannheim, Germany) was added and washed. Slides were then processed by the automated Tissue-Tek® Prisma®/Film® (Sakura, AJ Alphen aan den Rijn, Netherlands).
Quantification of double immunostained CD25+Foxp3+Treg cells was performed using Nikon Eclipse E400 microscope (8 fields in 400X corresponding to 2mm2; values were then divided by 2 to represent counts in 1mm2). All quantifications of Treg positive cells were performed by one observer with vast expertise in dermatopathology (MBC), blinded to the patients’ group. Immunostained cells were quantified in areas with and without inflammatory infiltrates and double stained Treg cells were visualized as brown/golden cytoplasm stained by anti CD25 revealed with DAB and violet/magenta nuclei stained Foxp3 revealed by alkaline phosphatase.
Immunohistochemistry to cytokines detection
Immunostaining of cytokines employed rabbit polyclonal antibodies to human TGF-β1, IFN-γ, IL-17 and IL-10 (Santa Cruz Biotechnology CA, USA). In brief, after deparaffinization, rehydration and blockade of endogenous peroxidase activity and antigen-retrieval, 3-4um sections of skin biopsies were incubated individually for 1 h with rabbit polyclonal antibodies to human TGF-β, IFN-γ, IL-17 and IL-10. Then, the primary antibody–HRP labeled complex (anti-human monoclonal antibody, clone 4C9, Ventana, Roche, Tucson, AZ, USA) was incubated (30 minutes). Color was developed using diaminobenzidine (DAB, Invitrogen Cat. N° 00–2014) chromogen system (5 minutes). Slides were washed and hematoxylin (Roche, Mannheim, Germany) was added, incubated and washed. For each cytokine, positive and negative controls were performed and the numbers of positive cells were counted by examining 1000 cells from multiple fields using Nikon Eclipse E400 microscope (200X). One observer with vast expertise in dermatopathology (MBC) performed all quantifications of cell associated-cytokines blinded to the participants’ clinical status.
Exploratory data analysis, including dot plot, box plot, means and medians were used to analyze the quantifications of Treg cells/mm2 and cytokine positive cells among different study groups. We have done a step by step comparison, first analyzing all reactional lesions together versus all reaction-free lesions. From the differences seen in these analyzes, we have conducted further comparisons which were based on stratified groups of patients: T1R versus reaction-free, and T2R versus reaction-free ones and then the T1R, T2R paired analyzes. The fold increase was based on the median values of Treg cells in each group and it was calculated by dividing the higher median number of Tregs by the lower median number of Tregs in each specific case. Statistical significance was assessed by Kruskall-Wallis one way analysis of variance for comparison of multiple groups and Mann-Whitney for comparison between two groups. Results were considered statistically significant when p-values <0.05 were obtained.
This study was approved by the regional and the national review boards (“Comitê de Ética em Pesquisa Humana e Animal do Hospital das Clínicas da Universidade Federal de Goiás”, protocol# 119/2005 and “Comissão Nacional de Ética e Pesquisa/CONEP/Brasil”, protocols # 4862, 12962). All patients signed an informed consent form before joining the study.
CD25+Foxp3+Treg cell numbers in T1R, T2R compared to reaction-free lesions
Higher Treg cell numbers were seen in reactional (28 T1R+12 TR2; n = 40) versus the same 40 reaction-free patients (p = 0.002) (Fig 1A). A higher number of Treg cells was observed in 56 T1R patients (28 had paired reactional and reaction-free samples and 28 had an individual reactional biopsy) compared to 40 reaction-free patients (28 reaction-free samples of patients that had T1R + 12 reaction-free samples of patients that had T2R) (p<0.0001) (Fig 1B). However, no difference in Treg cell counts was observed comparing 18 patients with T2R and 40 patients from the reaction-free group (28 reaction-free samples of patients that had T1R + 12 reaction-free samples of patients that had T2R) (Fig 1C). Comparison between T1R (n = 28) and T2R (n = 12) showed higher Treg cell counts in T1R lesions (p = 0.04) (Fig 1D). A two-fold increase in Treg numbers was seen in T1R compared to T2R (T1R: 42cells/mm2, T2R: 18.5cells/mm2).
(A) CD25+ Foxp3+Treg cell counts in skin biopsies of T1R+T2R (n = 40) and reaction-free leprosy patients (n = 40). (B) CD25+ Foxp3+Treg cell counts in biopsies of 56 T1R and 40 unpaired reaction-free patients. (C) CD25+ Foxp3+Treg cell counts in biopsies of 18 T2R and 40 unpaired reaction-free patients. (D) CD25+ Foxp3+Treg cells in biopsies of 28 T1R and 12 T2R. The horizontal lines represent the median CD25+ Foxp3+Treg cell counts.
Intra-individual comparisons in paired reactional and reaction-free biopsies showed higher numbers of Treg in lesions during T1R episodes (p = 0.001) (Fig 2A and 2B). A nine-fold increase of Treg cells was seen during T1R (reaction-free: 4.5cells/mm2 versus RT1: 41.5cells/mm2). In T2R and paired reaction-free lesions intra-individual comparisons showed no difference on Treg cell numbers (reaction-free: 16.5cells/mm2 versus T2R lesions: 21.5cells/mm2, p>0.05) (Fig 2C and 2D). Fig 2 depicts the immunostaining for CD25+ Foxp3+Treg cells in paired samples of a reaction-free BT patient (Fig 2E) and during T1R (Fig 2F); CD25+ Foxp3+Treg cells in paired samples of a BL reaction-free patient (Fig 2G) and during T2R (Fig 2H).
(A-B): CD25+ Foxp3+Treg cell counts in paired biopsies of T1R and reaction-free patients. The horizontal lines represent the median CD25+ Foxp3+Treg cell counts. (C-D): CD25+ Foxp3+Treg cell counts in paired biopsies of T2R and reaction-free patients. (E-F): CD25+ Foxp3+Treg cells in paired biopsies of a reaction-free BT lesion and during T1R; (G-H): CD25+ Foxp3+Treg cells in paired biopsies of a reaction-free BL patient and during a T2R. Marks: 50μm.
Increased numbers of Tregs cells in T1R were seen regardless of the moment when the reaction occurred either at diagnosis or during MDT. In T2R, similar Treg counts were observed regardless of the timing of development of reactions, at diagnosis or during MDT (data not show).
In situ expression of TGF-β, IL-17 and IFN-γ in T1R, T2R and reaction-free leprosy lesions
We have investigated the in situ expression of TGF-β, IL-17, IL-10 and IFN-γ in paired T1R/ reaction-free lesions (n = 12) and paired T2R (n = 12)/reaction-free lesions. Despite proper standardization of IL-10 staining in positive control samples from human intestine which were run in parallel, no IL-10 staining was seen in leprosy T1R or T2R or reaction-free lesions, while adequate staining for TGF-β, IL-17 and IFN-γ was achieved in leprosy lesions.
The TGF-β expression was increased in T2R lesions compared to RT1 (p = 0.017) and compared to all reaction-free lesions (p = 0.038) (Fig 3A). Similarly, IL-17 expression was higher in T2R lesions compared to T1R (p = 0.04). Statistically significant difference in IL-17 expression was observed comparing T2R lesions to all reaction-free lesions (p = 0.01) (Fig 3B). However, no significant intra-individual difference in IL-17 or TGF-β expression was observed comparing paired T1R-reaction free or T2R-reaction-free samples. So, while higher expression of IL-17 and TGF-β and was seen in T2R compared to T1R lesion, the expression of IFN-γ was similar in T1R, T2R and reaction-free lesions (Fig 3C). In situ immunostaining for TGF-β, IL-17 and IFN-γ in paired skin biopsies of T1R-reaction free and T2R-reaction-free lesions is shown in Fig 4.
Comparison of the expression of TGF-β (A) IL-17 (B) and IFN-γ (C) in paired skin biopsies of reactional (T1R and T2R) and reaction-free lesions. The horizontal lines represent the median counts of TGF-βL-17 and IFN-γ positive cells.
(A-B): TGF-βin paired biopsies of a patient during T1R and when the patient was reaction-free. (C-D): TGF-βin paired skin biopsies of a patient during T2R and when the patient was reaction-free. (E-F): IL-17 in paired skin biopsies of a patient with T1R and when the patient was reaction-free. (G-H): IL-17 in paired skin biopsies of a patient with T2R and when the patient was reaction-free. (I-J): IFN-γ in paired skin biopsies of a patient with T1R and when the patient was reaction-free. (K-L): IFN-γ in paired skin biopsies of a patient with T2R and when the patient was reaction-free.
Our study evaluated the in situ expression of both double positive CD25+ Foxp3+ Treg cells and cytokines in leprosy T1R and T2R with special emphasis on the frequency of Treg cells in paired biopsies collected in the absence of reaction and during the course of a reactional episode. The choice of the control group is a crucial component of comparative studies and we consider that intra-individual comparisons in reactional and reactional-free lesions are probably the best approach to investigate the impact of leprosy reactions upon Treg cell expression. In this study, paired sample analyses have shown an increased expression of Treg during T1R. On the other side, no impact on the lesional expression of Treg cells was seen in T2R.
A previous study showed similar results of increased frequency of Treg cells on five paired samples of T1R but in eight paired samples of T2R, results have shown decreased Treg cell numbers in TR2  contrasting with our results of similar frequencies of Treg with or without T2R. Our results of paired analysis together with other studies indicate that the in situ expression of Treg during T2R is either unchanged or decreased. Overall these findings of unchanged or decreased Treg during T2R are compatible with the extensive and somehow uncontrolled clinical manifestations associated with T2R. Under the circumstances of decreased/stable Treg cells expression wider tissue and nerve damage might occur. On the other side, our results of increased Treg numbers during T1R suggest a possible suppressive Treg role to control the exacerbated cell mediated immunity seen in T1R with beneficial rather than detrimental consequences to the host suggesting the possibility of modulating Treg for T1R therapy. However, the challenge remains to translate these laboratory findings of T cell populations and cytokines into the identification of clinically applicable immuno-markers associated with the clinical outcome of leprosy reactions.
Our results have shown increased expression of IL-17 and TGF-β in lesions with T2R compared to T1R and reaction-free lesions. TGF-β along with other pro-inflammatory cytokines (such as IL-6, IL-21 and IL-1β) are known to drive naïve T cells towards Th17 differentiation . Our findings suggest that in T2R, TGF-β may be implicated in the differentiation of Th17 cells however, this hypothesis needs to be confirmed by the investigation of the expression of IL-1β and IL-6. A recent study suggested that IL-12 and IL-23 modulate the plasticity of FoxP3+ Treg cells in leprosy, converting Treg cells into Th1 and Th17 . Another report on plasticity of T cells showed that the equilibrium between Th17 and Treg cells in leprosy reactions is disturbed with an increase in Th17 cells which leads to the inflammation and immunopathology associated with T2R . In our study, besides the stable numbers of Treg cells in T2R, the cytokine data indicate that T2R is associated with IL-17, which is a surrogate marker of Th17 activation. Altogether our results of Treg and cytokines expression during leprosy reactions are suggestive of Th17-Treg plasticity however, further experimental studies are required to confirm our hypothesis. T1R and T2R are recognized by extensive differences in the clinical presentation and in the heir histopathological profiles and the role of Treg and Th17 during these episodes is only elusive. Although T1R can occur in any leprosy form, it is more frequent in patients with robust Th1-Th17 immunity, but studies have shown that during T1R, their lesional immune profiles change to Th1-Treg cells. On the other side, T2R occur mainly in patients expressing Th2-Treg immunity, but there are evidences that during T2R their lesional immune profiles convert to Th1-Th17 cells. Therefore, our results corroborate the hypothesis that T2R occurs in a context of stable or decreased Treg and increased Th17 or conversion of Treg into Th17. Nevertheless, so far it is not possible to figure out to which extent the differential expression of Th17 and Treg during TR1 or T2R might be associated with the clinical outcome associated with reactions including nerve and tissue damage, independently of the anti-reaction treatment.
In general, studies evaluating circulating Treg cells suggest an increase of Treg cells during T1R episodes and a decrease in T2R patients, although contradictory results have also been described. These studies may not be comparable for numerous reasons. Different laboratory methodologies and distinct cell markers have been used to identify Treg cell phenotype (CD3, CD4, CD8, CD25, Foxp3, CD127, co-stimulatory molecules). Flow cytometry for surface and or intracellular staining has been used with different gating and acquisition strategies [15, 16, 19, 23]. Also, immunostaining for different Treg cell markers and PCR to investigate the expression of different genes have also been described. Treg expression in leprosy reactions has been described in distinct body compartments either in situ Treg in biopsies of skin lesions or circulating systemic Treg in unstimulated fresh and in fresh or thawed stimulated cells [14, 16–18, 24]. Additionally, different antigen preparations have been used for culture stimulation (ML sonicate, PHA) [16, 20]. More importantly, the different compositions of control groups used in the studies clearly impact comparisons. Leprosy reactions have been compared to non-reactional leprosy with similar clinical forms, non-reactional leprosy with all clinical forms, exposed contacts or even healthy individuals. Study groups have included different sample sizes, naïve and MDT treated patients and T2R treated with prednisolone [14, 16, 17, 19, 20, 23]. Although each methodological approach and study design may have advantages and disadvantages, it’s possible that intra-individual paired reaction-free/reactional lesions, as shown in this study, illustrate better the impact of leprosy reaction upon the expression of different T cell populations and cytokines in skin lesions.
One of the first studies about Treg and leprosy reactions indicated a reduced frequency of Treg cells in patients with T2R (n = 6) compared to non-reactional disease forms (BT, TT, BB, BL, LL) . Another study in 43 untreated leprosy patients (TT, BB, LL, T1R, T2R and pure neuritic form) and 40 healthy subjects (controls group) using flow cytometry showed higher expression of circulating Treg cells in patients with T1R . A decrease in Treg cells in T1R and T2R was shown by flow cytometry on PBMCs stimulated with sonicated M. leprae when compared to controls (non-reactional leprosy) . However, Foxp3 gene expression by quantitative PCR was increased in stimulated PBMC from T1R and T2Rcompared to patients with stable disease. A recent case-control study using flow cytometry and PBMCs in patients with T2R (n = 46) compared to matched non-reactional LL patient controls (n = 31) showed lower rate of CD4+ Treg cells before prednisolone treatment . A retrospective immunostaining study on 20 leprosy cases (TT, BT, BL, LL, BB-T1R, BT-T1R and T2R) showed higher expression of Treg cells in patients affected by T1R (n = 3) compared with patients affected by T2R (n = 3) and reaction-free patients . Immunostaining in 96 leprosy lesions of different forms (Indeterminate/I, TT, BT, BB, BL, LL), T1R (n = 8) and T2R (n = 2) also found an increment of Foxp3 expression in T1R compared to unreactional lesions (I, BT and LL forms) . Recently, the expression of cytokines related to Treg cell profile was evaluated by quantitative PCR in 87 skin biopsies from leprosy patients and showed decreased Treg cells markers in T1R and increased IL-17F, CCL20 and IL-8 in T2R when compared to the respective non-reactional leprosy patients .These apparently conflicting results are difficult to be compared may reflect the different methodological approaches and comparison groups used.
In conclusion, our study in paired skin biopsies before and during reaction showed increased numbers of Treg cells during T1R suggesting its beneficial role in the control of exacerbated inflammation and cellular immunity and consequent pathology seen in T1R. On the other hand, we showed stable Treg and an increase of IL-17 pro-inflammatory cytokine in T2R leprosy lesions suggesting the involvement of Th17 cells. Our results suggest a possible plasticity of Treg-Th17 populations in leprosy reactions. In human infectious diseases Treg cells may function like as a “double-edged sword” in which both the host and the pathogen may benefit from their function. The pathogen advantage would be because Treg reduces effector immunity leading to disease chronicity. The host advantage can be due to suppressive Treg activity limiting tissue damage caused by inflammation and tissue/nerve damage that occur in leprosy reactions.
- 1. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19(2):338–81. pmid:16614253.
- 2. Smith CS, Aerts A, Saunderson P, Kawuma J, Kita E, Virmond M. Multidrug therapy for leprosy: a game changer on the path to elimination. Lancet Infect Dis. 2017;17(9):e293–e7. Epub 2017/07/12. doi: S1473-3099(17)30418-8 [pii] pmid:28693853.
- 3. WHO. Global leprosy update 2016: accelerating reduction of disease burden. Geneva 2017. p. 501–20.
- 4. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966;34(3):255–73. pmid:5950347.
- 5. Saini C, Tarique M, Rai R, Siddiqui A, Khanna N, Sharma A. T helper cells in leprosy: An update. Immunol Lett. 2017;184:61–6. Epub 2017/02/27. doi: S0165-2478(17)30093-7 [pii] pmid:28235552.
- 6. Modlin RL, Melancon-Kaplan J, Young SM, Pirmez C, Kino H, Convit J, et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci U S A. 1988;85(4):1213–7. Epub 1988/02/01. pmid:3257577; PubMed Central PMCID: PMC279737.
- 7. Saini C, Ramesh V, Nath I. CD4+ Th17 cells discriminate clinical types and constitute a third subset of non Th1, Non Th2 T cells in human leprosy. PLoS Negl Trop Dis. 2013;7(7):e2338. Epub 2013/08/13. PNTD-D-13-00665 [pii]. pmid:23936569; PubMed Central PMCID: PMC3723566.
- 8. Quaresma JA, Aarao TL, Sousa JR, Botelho BS, Barros LF, Araujo RS, et al. T-helper 17 cytokines expression in leprosy skin lesions. Br J Dermatol. 2015;173(2):565–7. Epub 2014/12/17. pmid:25495069.
- 9. Bobosha K, Wilson L, van Meijgaarden KE, Bekele Y, Zewdie M, van der Ploeg-van Schip JJ, et al. T-cell regulation in lepromatous leprosy. PLoS Negl Trop Dis. 2014;8(4):e2773. pmid:24722473; PubMed Central PMCID: PMC3983090.
- 10. Saini C, Ramesh V, Nath I. Increase in TGF-beta secreting CD4(+)CD25(+) FOXP3(+) T regulatory cells in anergic lepromatous leprosy patients. PLoS Negl Trop Dis. 2014;8(1):e2639. Epub 2014/01/24. PNTD-D-13-01037 [pii]. pmid:24454972; PubMed Central PMCID: PMC3894184.
- 11. Palermo ML, Pagliari C, Trindade MA, Yamashitafuji TM, Duarte AJ, Cacere CR, et al. Increased expression of regulatory T cells and down-regulatory molecules in lepromatous leprosy. Am J Trop Med Hyg. 2012;86(5):878–83. pmid:22556091.
- 12. Kumar S, Naqvi RA, Ali R, Rani R, Khanna N, Rao DN. CD4+CD25+ T regs with acetylated FoxP3 are associated with immune suppression in human leprosy. Mol Immunol. 2013;56(4):513–20. Epub 2013/08/06. S0161-5890(13)00170-3 [pii]. pmid:23911408.
- 13. Rodrigues LC, Lockwood D. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis. 2011;11(6):464–70. pmid:21616456.
- 14. Massone C, Nunzi E, Ribeiro-Rodrigues R, Talhari C, Talhari S, Schettini AP, et al. T regulatory cells and plasmocytoid dentritic cells in hansen disease: a new insight into pathogenesis? Am J Dermatopathol. 2010;32(3):251–6. pmid:20075708.
- 15. Attia EA, Abdallah M, Saad AA, Afifi A, El Tabbakh A, El-Shennawy D, et al. Circulating CD4+ CD25 high FoxP3+ T cells vary in different clinical forms of leprosy. Int J Dermatol. 2010;49(10):1152–8. pmid:20883403.
- 16. Saini C, Siddiqui A, Ramesh V, Nath I. Leprosy Reactions Show Increased Th17 Cell Activity and Reduced FOXP3+ Tregs with Concomitant Decrease in TGF-beta and Increase in IL-6. PLoS Negl Trop Dis. 2016;10(4):e0004592. Epub 2016/04/02. PNTD-D-16-00085 [pii]. pmid:27035913; PubMed Central PMCID: PMC4818038.
- 17. Parente JN, Talhari C, Schettini AP, Massone C. T regulatory cells (TREG)(TCD4+CD25+FOXP3+) distribution in the different clinical forms of leprosy and reactional states. An Bras Dermatol. 2015;90(1):41–7. Epub 2015/02/13. S0365-05962015000100041 [pii]. pmid:25672298; PubMed Central PMCID: PMC4323697.
- 18. Azevedo MCS, Marques H, Binelli LS, Malange MSV, Devides AC, Silva EA, et al. Simultaneous analysis of multiple T helper subsets in leprosy reveals distinct patterns of Th1, Th2, Th17 and Tregs markers expression in clinical forms and reactional events. Med Microbiol Immunol. 2017;206(6):429–39. Epub 2017/09/07. 10.1007/s00430-017-0519-9 [pii]. pmid:28875310.
- 19. Vieira AP, Trindade MA, Pagliari C, Avancini J, Sakai-Valente NY, Duarte AJ, et al. Development of Type 2, But Not Type 1, Leprosy Reactions is Associated with a Severe Reduction of Circulating and In situ Regulatory T-Cells. Am J Trop Med Hyg. 2016;94(4):721–7. Epub 2016/02/24. [pii]. pmid:26903606; PubMed Central PMCID: PMC4824210.
- 20. Negera E, Walker SL, Bobosha K, Howe R, Aseffa A, Dockrell HM, et al. T-cell regulation in Erythema Nodosum Leprosum. PLoS Negl Trop Dis. 2017;11(10):e0006001. Epub 2017/10/11. PNTD-D-17-01102 [pii]. pmid:28991896; PubMed Central PMCID: PMC5648259.
- 21. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40(7):1830–5. Epub 2010/06/29. pmid:20583029.
- 22. Tarique M, Saini C, Naqvi RA, Khanna N, Sharma A, Rao DN. IL-12 and IL-23 modulate plasticity of FoxP3+ regulatory T cells in human Leprosy. Mol Immunol. 2017;83:72–81. Epub 2017/01/23. doi: S0161-5890(17)30008-1 [pii] pmid:28110210.
- 23. Attia EA, Abdallah M, El-Khateeb E, Saad AA, Lotfi RA, El-Shennawy D. Serum Th17 cytokines in leprosy: correlation with circulating CD4(+) CD25 (high)FoxP3 (+) T-regs cells, as well as down regulatory cytokines. Arch Dermatol Res. 2014;306(9):793–801. Epub 2014/07/16. pmid:25018055.
- 24. Fachin LR, Soares CT, Belone AF, Trombone AP, Rosa PS, Guidella CC, et al. Immunohistochemical assessment of cell populations in leprosy-spectrum lesions and reactional forms. Histol Histopathol. 2017;32(4):385–96. Epub 2016/07/23. [pii]. pmid:27444702.